Mesoblast Limited (ASX:MSB)
2.400
-0.090 (-3.61%)
Sep 26, 2025, 4:10 PM AEST
Mesoblast Revenue
In the fiscal year ending June 30, 2025, Mesoblast had annual revenue of $17.20M USD with 191.39% growth. Mesoblast had revenue of $14.04M in the half year ending June 30, 2025, with 244.25% growth.
Revenue
$17.20M
Revenue Growth
+191.39%
P/S Ratio
117.10
Revenue / Employee
$212.32K
Employees
81
Market Cap
3.07B AUD
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2025 | 17.20M | 11.30M | 191.39% |
Jun 30, 2024 | 5.90M | -1.60M | -21.32% |
Jun 30, 2023 | 7.50M | -2.71M | -26.54% |
Jun 30, 2022 | 10.21M | 2.78M | 37.36% |
Jun 30, 2021 | 7.43M | -24.72M | -76.88% |
Jun 30, 2020 | Pro | Pro | Pro |
Jun 30, 2019 | Pro | Pro | Pro |
Jun 30, 2018 | Pro | Pro | Pro |
Jun 30, 2017 | Pro | Pro | Pro |
Jun 30, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
CSL Limited | 23.73B |
Pro Medicus | 212.98M |
Cochlear | 2.34B |
Sonic Healthcare | 9.65B |
Ramsay Health Care | 17.79B |
Telix Pharmaceuticals | 1.01B |
Ansell | 3.06B |
Neuren Pharmaceuticals | 218.86M |
Mesoblast News
- 2 days ago - Mesoblast Cell Therapy Products are Designated U.S. Origin and Not Subject to Tariffs - GlobeNewsWire
- 13 days ago - Successful Commercial Launch of Ryoncil® Highlighted at Global Healthcare Conferences - GlobeNewsWire
- 24 days ago - Mesoblast enters option to issue $50M convertible notes - Seeking Alpha
- 24 days ago - Mesoblast Enters Into Option To Issue US$50 Million Convertible Notes - GlobeNewsWire
- 4 weeks ago - Mesoblast Limited (MESO) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Mesoblast Limited 2025 Q4 - Results - Earnings Call Presentation - Seeking Alpha
- 4 weeks ago - Full Year 2025 Mesoblast Ltd Earnings Presentation Transcript - GuruFocus
- 4 weeks ago - Mesoblast (MESO) Sees Revenue Surge in FY25 with Ryoncil's FDA Approval - GuruFocus